Abstract
Rationale
Although naltrexone has been widely researched in the context of drinking and smoking behaviors, with each substance studied separately, little is known about the effects of naltrexone on craving for cigarettes during alcohol intoxication.
Objectives
The present study used a within-subjects double-blind placebo-controlled design to (1) examine the effects of alcohol, administered intravenously, on craving for cigarettes; (2) test the effects of naltrexone on cigarette craving during alcohol intoxication; and (3) examine the relationship between craving for alcohol and cigarettes across rising breath alcohol concentrations (BrACs).
Materials and methods
Heavy drinking light smokers completed two counterbalanced intravenous alcohol challenge sessions, one after taking naltrexone (50 mg) for 3 days and one after taking a placebo for 3 days. During each session, participants reported on their craving for alcohol and cigarettes.
Results
Analyses revealed a significant positive effect of BrAC on urge to smoke as well as a BrAC × Medication interaction. Specifically, the linear relationship between BrAC and urge to smoke was significantly weaker in the naltrexone condition, as compared to placebo. There was also a positive association between urge to drink and urge to smoke, and this relationship was moderated by BrAC.
Conclusions
These findings demonstrate that the pharmacological effects of alcohol alone induce craving for cigarettes and that naltrexone blunts the progression of craving for cigarettes during alcohol intoxication. These results highlight the potential clinical utility of naltrexone for heavy drinkers trying to quit smoking.
Similar content being viewed by others
References
Allen JP, Litten RZ, Fertig JB, Babor T (1997) A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcohol Clin Exp Res 21:613–619
Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156:1758–1764
Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D (2004) Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology 173:32–40
Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donavan DM et al (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence, the COMBINE study: a randomized controlled trial. JAMA 295:2003–2017
Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J et al (2003) A 6-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27:1142–1149
Barrett SP, Tichauer M, Leyton M, Pihl RO (2006) Nicotine increases alcohol self-administration in non-dependent male smokers. Drug Alcohol Depend 81:197–204
Bjartveit K, Tverdal A (2005) Health consequences of smoking 1–4 cigarettes per day. Tob Control 14:315–320
Burton SM, Tiffany ST (1997) The effect of alcohol consumption on craving to smoke. Addiction 92:15–26
Byars JA, Frost-Pineda K, Jacobs WS (2005) Naltrexone augments the effects of nicotine replacement therapy in female smokers. J Addict Dis 24:49–60
Covey LS, Glassman AH, Stetner F (1999) Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 18:31–40
Davidson RJ (2003) Affective neuroscience and psychophysiology: toward a synthesis. Psychophysiology 44:655–665
Davidson D, Swift R, Fitz E (1996) Naltrexone increase the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 20:732–739
Dawson DA (2000) Drinking as a risk factor for sustained smoking. Drug Alcohol Depend 59:235–249
Del Boca FK, Kranzler HR, Brown J, Korner PF (1996) Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 20:1412–1417
Drobes DJ, Anton RF, Thomas SE, Vornin K (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28:1362–1370
Epstein AM, King AC (2004) Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav 77:29–37
Epstein AM, Sher TG, Young MA, King AC (2007) Tobacco chippers show robust increases in smoking urge after alcohol consumption. Psychopharmacology 190(3): 321–329
Glautier S, Clements K, White JA, Taylor C, Stolerman IP (1996) Alcohol and the reward value of cigarette smoking. Behav Pharmacol 7:144–154
Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M et al (2002) A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 26:1381–1387
Hutchison KE, Monti PM, Rohsenow DJ, Swift R, Colby SM, Gnys M, Niaura RS, Sirota AD (1999) Effects of naltrexone with nicotine replacement on smoking cue-reactivity: preliminary results. Psychopharmacology 142:139–143
Kahler CW, Resendes A, Monti PM, Ramsey SE, Abrams DA, Brown RA (2005) Alcohol use and smoking outcomes among heavy drinkers in smoking cessation treatment. In: Society for Research on Nicotine and Tobacco Annual Meeting, Prague, Czech Republic
King AC, Epstein AM (2005) Alcohol dose-dependent increases in smoking urge in light smokers. Alcohol Clin Exp Res 29:547–552
King AC, Meyer PJ (2000) Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav 66:563–572
King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D (2006) Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res 8:671–682
Kouri EM, McCarthy EM, Faust AH, Lukas SE (2004) Pretreatment with transdermal nicotine enhances some of ethanol's acute effects in men. Drug Alcohol Depend 75(1):55–65
Lee YS, Joe KH, Sohn IK, Na C, Kee BS, Chae SL (2005) Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment. Prog Neuropsychopharmacol Biol Psychiatry 29:639–647
Li T, Yin S, Crabb DW, O’Connor S, Ramchandani VA (2001) Genetic and environmental influences on alcohol metabolism in humans. Alcohol Clin Exp Res 25:136–144
Littleton J, Zieglgansberger W (2003) Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 12:3–11
McCaul ME, Wand GS, Stauffer R, Lee SM, Rohde CA (2001) Naltrexone dampens ethanol-induced cardiovascular and hypothalamic–pituitary–adrenal axis activation. Neuropsychopharmacology 25:537–547
Mello NK, Mendelson JH, Sellers ML, Kuehnle JC (1980) Effect of alcohol and marijuana on tobacco smoking. Clin Pharmacol Ther 27:202–209
Mitchell SH, de Wit H, Zacny JP (1995) Effects of varying ethanol dose on cigarette consumption in healthy normal volunteers. Behav Pharmacol 6:359–365
Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM et al (1999) Naltrexone’s effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23:1386–1394
Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI et al. (2001) Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcohol Clin Exp Res 25:1634–1647
Ockene JK, Adams A (1995) Screening and intervention for smoking and alcohol use in primary care settings: similarities, differences, gaps, and challenges. In: Fertig JB, Allen JP (eds) Alcohol and tobacco: from basic science to clinical practice. National Institutes of Health, Bethesda, MD, pp 281–294
O’Connor S, Morzorati S, Christian J, Li T (1998) Clamping breath alcohol concentration reduces experimental variance: Application to the study of acute tolerance to alcohol and alcohol elimination rate. Alcohol Clin Exp Res 22:202–210
O’Malley SS, Jaffe AJ, Change G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49:881–887
O’Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL et al (2006) A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med 166:667–674
Perkins KA, Sexton JE, DiMarco A, Grobe JE, Scierka A, Stiller RL (1995) Subjective and cardiovascular responses to nicotine combined with alcohol in male and female smokers. Psychopharmacology 119:205–212
Ramchandani VA, Bolane J, Li TK, O’Connor S (1999) A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. Alcohol Clin Exp Res 23:617–623
Ray LA, Hutchison KE (2004) A polymorphism of the mu-opioid receptor gene and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28:1789–1795
Ray LA, Hutchison KE (2007) A double-blind placebo-controlled study of the effects of naltrexone on alcohol sensitivity and genetic moderators of medication response. Arch Gen Psychiatry, in press
Ray LA, McGeary J, Marshall E, Hutchison KE (2006) Risk factors for alcohol misuse: integrating heart rate response to alcohol, alcohol sensitivity, and personality factors. Addict Behav 31:1959–1973
Ray LA, Meskew-Stacer S, Hutchison KE (2007) The relationship between prospective self-rating of alcohol sensitivity and craving and experimental results from two alcohol challenge studies. J Stud Alcohol Drugs 68(3)379–384
Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC (1995) Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. Br Med J 310:555–559
Rohsenow DJ, Monti PM, Colby SM, Gulliver SB, Swift RM, Abrams DB (2003) Naltrexone treatment for alcoholics: effect on cigarette smoking rates. Nicotine Tob Res 5:231–236
Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, MacKinnon SV, Sirota AD et al (2007) High dose transdermal nicotine and naltrexone: Effects on nicotine withdrawal, urges, smoking, and effects of smoking. Exp Clin Psychopharmacol 15(1):81–92
Rose JE, Brauer LH, Behm FM, Cramblett M, Calkins K, Lawhon D (2002) Potentiation of nicotine reward by alcohol. Alcohol Clin Exp Res 6:930–1931
Rose JE, Brauer LH, Behm FM, Cramblett M, Calkins K, Lawhon D (2004) Psychopharmacological interactions between nicotine and ethanol. Nicotine Tob Res 6:133–144
Rubio G, Manzanares J, Lopez-Munoz F, Alamo C, Ponce G, Jimenez-Arriero, MA, Palomo T (2002) Naltrexone improves outcome of a controlled drinking program. J Subst Abuse Treat 23:361–366
Rukstalis M, Jepson C, Strasser A, Lynch KG, Perkins K, Patterson F et al (2005) Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology 180:41–48
SAS Institute 2003. The SAS system for windows (version 8.2) SAS Institute, Cary, NC
Sayette MA, Martin CS, Wertz JM, Perrott MA, Peters AR (2005) The effects of alcohol on cigarette craving in heavy smokers and tobacco chippers. Psychol Addict Behav 19:263–270
Schoenborn CA, Adams PF, Barnes PM, Vickerie JL, Schiller JS (2004) Health behaviors of adults: United States, 1999–2001. Vital Health Stat 10(219):1–79
Shiffman S, Fischer LA, Paty JA, Gnys M, Hickcox M, Kassel JD (1994) Drinking and smoking: a field study of their association. Annals Behav Med 16:203–209
Strizke WGK, Breiner MJ, Curtin JJ, Lang AR (2004) Assessment of substance cue reactivity: advances in reliability, specificity, and validity. Psychol Addict Behav 18:148–159
Sutherland G, Stapleton JA, Russell MA, Feyerabend C (1995) Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology 120:418–425
Swift RM, Whelihan W, Kusnetsov O, Buongiorno G, Hsuing H (1994) Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 151:1463–1467
Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876–880
Wewers ME, Dhatt R, Tejwani GA (1998) Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology 140:185–190
White HR, Labouvie EW (1989) Towards the assessment of adolescent problem drinking. J Stud Alcohol 50:30–37
Acknowledgements
The authors would like to acknowledge the assistance of Amy Audette, Stephanie Dicristoforo, Keira Odell, and Jenifer Bishop on data collection for this project. The authors also wish to thank the staff at the General Clinical Research Center at the University of Colorado, at Boulder.
The authors would like to state that the study described in this manuscript complied with the current laws of the USA.
Grant support: This research was supported by grants from the National Institute on Alcoholism and Alcohol Abuse to L. A. R. (AA14847) and K. E. H. (AA012238) and by a grant from the General Clinical Research Center Program of the National Center for Research Resources, National Institutes of Health (M01-RR00051).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ray, L.A., Miranda, R., Kahler, C.W. et al. Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharmacology 193, 449–456 (2007). https://doi.org/10.1007/s00213-007-0794-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-007-0794-z